Ruxolitinib as front-line therapy in graft versus host disease: Efficacy and safety in children

• Hoofdauteurs: Revathi Raj (Auteur), Venkateswaran Vellaichamy Swaminathan (Auteur), Satishkumar Meena (Auteur), Harika Varla (Auteur), Rumesh Chandar (Auteur), Balasubramaniam Ramakrishnan (Auteur), Ramya Uppuluri (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2021-12-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background: Ruxolinitib has been used as an effective salvage agent in steroid refractory acute and chronic graft versus host disease (GVHD). We aimed to analyze data on ruxolitinib as front-line therapy in children. Patients and methods: We included children up to 18 years of age who underwent hema...